The 10-second takeaway
For the quarter ended Dec. 31 (Q1), Avanir Pharmaceuticals met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.
Gross margins contracted, operating margins expanded, net margins grew.
Avanir Pharmaceuticals logged revenue of $16.5 million. The five analysts polled by S&P Capital IQ foresaw net sales of $16.4 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $7.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.09. The four earnings estimates compiled by S&P Capital IQ predicted -$0.08 per share. GAAP EPS were -$0.09 for Q1 against -$0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.9%, 80 basis points worse than the prior-year quarter. Operating margin was -66.8%, 15,600 basis points better than the prior-year quarter. Net margin was -73.1%, 14,950 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $18.4 million. On the bottom line, the average EPS estimate is -$0.07.
Next year's average estimate for revenue is $80.2 million. The average EPS estimate is -$0.17.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 187 members out of 248 rating the stock outperform, and 61 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Avanir Pharmaceuticals a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.50.
- Add Avanir Pharmaceuticals to My Watchlist.